[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-lesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-lesion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100566686","phase-2-clinical-trial-evaluating-secondary-hpv-vaccination-after-treatment-of-high-grade-cervical-lesions-100566686",false,"NCT06658405","Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","Phase 2 Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (HPV2-2303)","HPV2","Inclusion Criteria:\n\n1. Common eligibility criteria for the study (for both cohorts) :\n\n   1. Female patient over 45 years old\n   2. Patient treated by conization for high-grade cervical epithelial lesion\n   3. Positive HPV test at the 6-month post-operative control (a delay of 6 to 12 months will be accepted), leading to an indication for a control colposcopy (+\u002F- biopsy) according to standard surveillance practices.\n   4. N.B. : Patients with abnormalities at the initial control colposcopy and\u002For positive biopsy remain eligible for the study, whether vaccinated or not.\n2. Additional eligibility criteria for the clinical trial (Vaccinated patients cohort)\n\n   1. No contraindication to HPV vaccination with Gardasil 9\n   2. Patient consented to HPV vaccination with Gardasil 9\n   3. Affiliated with a social security system\n   4. Informed and signed written consent provided\n   5. N.B. : Patients infected with HIV are eligible for the vaccine trial provided they are on antiretroviral therapy.\n3. Inclusion criteria for the data study (Non-vaccinated patients cohort)\n\n   1. Patient eligible for the study (a) and not eligible for the clinical trial (b) due to:\n\n      * refusal of vaccination, or\n      * A contraindication to vaccination\n   2. No objection to the use of their personal data for research purposes\n\nN.B. : A patient who initially refused vaccination may later request to be vaccinated as part of the trial after signing the consent form. The vaccine trial analysis will include all patients who started vaccination within 6 months after the initial HPV control test.\n\nExclusion Criteria:\n\n1. Common exclusion criteria for the study (for both cohorts)\n\n   1. History of primary HPV vaccination\n   2. History of HPV-induced invasive cancer (cervical, vaginal, vulvar, anal, oropharyngeal cancer)\n2. Exclusion criteria for the clinical trial (Vaccinated patients cohort)\n\n   1. Patient refusing HPV vaccination\n   2. Patient with a contraindication to HPV vaccination with Gardasil 9\n   3. Patient deprived of liberty or under guardianship\n3. Exclusion criteria for the data study (Non-vaccinated patients cohort) a) Opposition to the use of their personal data for research purposes","FEMALE","45 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination.\n\nThe study includes two cohorts:\n\n1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2).\n2. Non-vaccinated patients will be included in a non-interventional observational study, with no changes to their standard care.",[27],"Cervical Lesion",[29,30,31,32,33],"HPV","oncology","secondary prevention","cervix","vaccination","RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2025-01-13",{"date":42,"type":21},"2031-12-31",{"name":44,"class":45},"Centre Oscar Lambret","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100537321","protein-molecular-characteristics-and-prognosis-of-cervical-neuroendocrine-tumors-100537321","NCT06276309","Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology\n2. Clinical data were complete\n\nExclusion Criteria:\n\n1. Patients who are not being treated in our hospital\n2. Patients with lack of follow-up data, unable to obtain survival information\n3. Patients call to refuse to participate in this project\n4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination",{"count":54,"type":21},300,"OBSERVATIONAL","The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.",[58,59,60,61,27],"Neuroendocrine Neoplasm","China","Women","Cervical Cancer","2024-09-12",{"date":64,"type":38},"2024-09-19",{"date":66,"type":38},"2024-02-01",{"date":68,"type":21},"2025-02-28",{"name":70,"class":45},"Fujian Maternity and Child Health Hospital",9,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100551734","a-clinical-trial-to-compare-lasotronix-alone-or-in-combination-with-cpp-acp-to-treat-dh-100551734","NCT06463938","A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH","A Clinical Study to Evaluate the Effectiveness of Casein Phosphopeptide, Amorphous Calcium Phosphate Paste (CPP-ACP) Used Alone or in Combination With Lasotronix (Diode Laser) to Treat Dentin Hypersensitivity","Inclusion criteria:\n\n* Patients of either gender, with ages between 25-65 years\n* should have at least more than one hypersensitive and vital tooth without any carious lesion or defective restoration\n\nExclusion criteria:\n\n* History of desensitizing therapy on the affected tooth\u002Fteeth in last six months (use of desensitizing toothpaste)\n* use of antibiotics \u002Fanalgesic\u002Fanti-inflammatory drugs\n* history of smoking\n* pregnancy\n* those who are not willing to participate or give follow-ups",true,"ALL","25 Years","65 Years",{"count":84,"type":21},120,[86],"NA","Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects\". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).",[89,90,27],"Dentin Sensitivity","Hypersensitivity",[89,92,93],"Lasotronix","Diode laser","2024-07-25",{"date":96,"type":38},"2024-07-26",{"date":98,"type":38},"2024-05-12",{"date":100,"type":21},"2024-10-10",{"name":102,"class":45},"Dow University of Health Sciences"]